25Suppliers
13Customers
3Debt Items
20Related Chains

Source-Backed Evidence Depth

Vaxart, Inc. (VXRT) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

42Total relationships
5Distinct source URLs
11High confidence
0.753Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Vaxart, Inc. Suppliers

TickerNameConfidenceEvidence
DAIICHI-SANKYO DAIICHI-SANKYO 92% The Company generates royalty revenue from the sale of Inavir in Japan, pursuant to a collaboration and license agreement that Aviragen entered into with Daiichi Sankyo Company, Limited
HCRP HCRP 90% We continue to have non-cash royalty revenue as all royalties received for the three months ended March 31, 2026 and 2025 were required to be paid to HCRP
LINCOLN-PARK LINCOLN-PARK 90% The Company will issue 447,067 shares of Common Stock (the "Commitment Shares") to Lincoln Park as consideration for its commitment to purchase shares of Common Stock under the Purchase Agreement.
UTAH-AVENUE-LANDLORD UTAH-AVENUE-LANDLORD 90% the Company agreed to lease from the Utah Avenue Landlord two additional suites in an additional building on Utah Avenue
HARBOR-WAY-LANDLORD HARBOR-WAY-LANDLORD 80% the Company entered into a termination agreement with another landlord (the “Harbor Way Landlord”) in connection with the termination of that certain lease agreement
AZN AstraZeneca PLC 72% irements relating to the organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and…
AZN AstraZeneca PLC 72% Reciprocal relationship from AZN graph: Reciprocal relationship from VXRT graph: irements relating to the organization of personnel, buildings and facilities, equipment, control of components and dru…
COCP Cocrystal Pharma, Inc. 72% ion, any success in preclinical testing we might observe for our COVID-19 vaccine candidates may not be predictive of the results of later-stage human clinical trials. Factors such as efficacy, immun…
COCP Cocrystal Pharma, Inc. 72% Reciprocal relationship from COCP graph: Reciprocal relationship from VXRT graph: Reciprocal relationship from COCP graph: Reciprocal relationship from VXRT graph: ion, any success in preclinical tes…
CSLLY CSL Limited 72% irements relating to the organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and…
CSLLY CSL Limited 72% Reciprocal relationship from CSLLY graph: Reciprocal relationship from VXRT graph: irements relating to the organization of personnel, buildings and facilities, equipment, control of components and d…
EBS Emergent BioSolutions Inc. 72% irements relating to the organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and…
EBS Emergent BioSolutions Inc. 72% Reciprocal relationship from EBS graph: Reciprocal relationship from VXRT graph: Reciprocal relationship from EBS graph: Reciprocal relationship from VXRT graph: Reciprocal relationship from EBS grap…
INO Inovio Pharmaceuticals, Inc. 72% irements relating to the organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and…
INO Inovio Pharmaceuticals, Inc. 72% Reciprocal relationship from INO graph: Reciprocal relationship from VXRT graph: irements relating to the organization of personnel, buildings and facilities, equipment, control of components and dru…
MRK Merck & Co., Inc. 72% Reciprocal relationship from MRK graph: Reciprocal relationship from VXRT graph: Reciprocal relationship from MRK graph: Reciprocal relationship from VXRT graph: irements relating to the organization…
MRK Merck & Co., Inc. 72% irements relating to the organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and…
NVSEF Novartis AG 72% Reciprocal relationship from NVSEF graph: Reciprocal relationship from VXRT graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from VXRT graph: Reciprocal relationship from NVSE…
NVSEF Novartis AG 72% irements relating to the organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and…
SGIOF Shionogi & Co., Ltd. 72% irements relating to the organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and…
SGIOF Shionogi & Co., Ltd. 72% Reciprocal relationship from SGIOF graph: Reciprocal relationship from VXRT graph: Reciprocal relationship from SGIOF graph: Reciprocal relationship from VXRT graph: irements relating to the organiza…
SNYNF Sanofi 72% irements relating to the organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and…
SNYNF Sanofi 72% Reciprocal relationship from SNYNF graph: Reciprocal relationship from VXRT graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from VXRT graph: Reciprocal relationship from SNYN…
SVA Sinovac Biotech Ltd. 72% Reciprocal relationship from SVA graph: Reciprocal relationship from VXRT graph: irements relating to the organization of personnel, buildings and facilities, equipment, control of components and dru…
SVA Sinovac Biotech Ltd. 72% irements relating to the organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and…

Vaxart, Inc. Customers

TickerNameConfidenceEvidence
DYNAVAX DYNAVAX 92% On November 4, 2025, the Company entered into the 2025 License and Collaboration Agreement with Dynavax relating to the Company's investigational oral vaccine candidate for COVID-19
HHS-BARDA HHS-BARDA 85% Revenue from government contracts consists of the 2024 ASPR-BARDA Contract awarded to us in January 2024 and the 2024 ATI-RRPV Contract awarded to us in June 2024
COCP Cocrystal Pharma, Inc. 72% Reciprocal relationship from COCP graph: Reciprocal relationship from VXRT graph: ion, any success in preclinical testing we might observe for our COVID-19 vaccine candidates may not be predictive of…
COCP Cocrystal Pharma, Inc. 72% ion, any success in preclinical testing we might observe for our COVID-19 vaccine candidates may not be predictive of the results of later-stage human clinical trials. Factors such as efficacy, immun…
SGIOF Shionogi & Co., Ltd. 72% Item 8) has no impact on total revenue recognized, it only impacts our net cash flow in the quarter following revenue recognition. We cannot predict with any certainty what our royalty revenues are l…
SGIOF Shionogi & Co., Ltd. 72% Reciprocal relationship from SGIOF graph: Reciprocal relationship from VXRT graph: Item 8) has no impact on total revenue recognized, it only impacts our net cash flow in the quarter following revenu…
SNYNF Sanofi 72% Reciprocal relationship from SNYNF graph: Reciprocal relationship from VXRT graph: greement and conducting additional development and manufacturing activities related to the Vaccine Candidate. On Feb…
SNYNF Sanofi 72% greement and conducting additional development and manufacturing activities related to the Vaccine Candidate. On February 10, 2026, Sanofi completed its acquisition of Dynavax. As a result of the con…
B-RILEY-SECURITIES-INC B-RILEY-SECURITIES-INC 62% ed March 31, 2026 2025 % Change Non-cash royalty revenue related to sale of future royalties $ 42 $ 1,579 (97 )% Revenue from government contracts 36,370 19,297 88 % Collaboration revenue 2,815 — — %…
CITIZENS-JMP-SECURITIES-LLC CITIZENS-JMP-SECURITIES-LLC 62% ed March 31, 2026 2025 % Change Non-cash royalty revenue related to sale of future royalties $ 42 $ 1,579 (97 )% Revenue from government contracts 36,370 19,297 88 % Collaboration revenue 2,815 — — %…
DAIICHI-SANKYO-COMPANY-LIMITED DAIICHI-SANKYO-COMPANY-LIMITED 62% ch 31, 2025, royalty payments fall below $3.0 million; and $2.7 million for the second royalty interest period of April 1, 2025 and ending on December 24, 2029, excluding the period of April 1, 2028 …
DYNAVAX-TECHNOLOGIES-CORPORATION DYNAVAX-TECHNOLOGIES-CORPORATION 62% ed March 31, 2026 2025 % Change Non-cash royalty revenue related to sale of future royalties $ 42 $ 1,579 (97 )% Revenue from government contracts 36,370 19,297 88 % Collaboration revenue 2,815 — — %…
LINCOLN-PARK-CAPITAL-FUND-LLC LINCOLN-PARK-CAPITAL-FUND-LLC 62% ed March 31, 2026 2025 % Change Non-cash royalty revenue related to sale of future royalties $ 42 $ 1,579 (97 )% Revenue from government contracts 36,370 19,297 88 % Collaboration revenue 2,815 — — %…

Vaxart, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
VXRT-DEBT-13478 Xbrl Convertible 90% xbrl convertible detail from xbrl 2018-12-31.
VXRT-DEBT Debt stack $17.7M 90% Market cache reports total debt of $17.7M.
VXRT-DEBT-13477 Warrants outstanding: 10454546 90% xbrl warrant detail from xbrl 2023-12-31.

Vaxart, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Vaxart, Inc..

Vaxart, Inc. Ownership

HolderNameConfidenceEvidence
VXRT-OWNER-LEONTEQ-SECURITIES-AG Leonteq Securities AG 90% 13F overlay lists Leonteq Securities AG as top holder; 7 tracked holders.

Vaxart, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
CALC CalciMedica, Inc. 100.00 2
CTMX CytomX Therapeutics, Inc. 100.00 2
REGN Regeneron Pharmaceuticals, Inc. 100.00 2
SVA Sinovac Biotech Ltd. 100.00 2 ['supplier']
ALXO ALX Oncology Holdings Inc. 100.00 2
CYTOF Altamira Therapeutics Ltd. 100.00 2
BLRX BioLineRx Ltd. 100.00 2
ATOS Atossa Therapeutics, Inc. 100.00 2
CYTK Cytokinetics, Incorporated 100.00 2
ANL Adlai Nortye Ltd. 100.00 2
CBIO Crescent Biopharma, Inc. 100.00 2
ANRO Alto Neuroscience, Inc. 100.00 2
CCEP Coca-Cola Europacific Partners PLC 100.00 2
DSGN Design Therapeutics, Inc. 100.00 2
AZN AstraZeneca PLC 100.00 2 ['supplier']
CSLLY CSL Limited 100.00 1 ['supplier']
DBVTF DBV TECHNOLOGIES 100.00 2
BIOA BioAge Labs, Inc. 100.00 2
EDIT Editas Medicine, Inc. 100.00 2
GRDX GridAI Technologies Corp. 100.00 2
🔐
VXRT
Unlock VXRT Supply Chain Data
Verified relationships include:
DAIICHI-SANKYODAIICHI-SANKYOSupplier92%
HCRPHCRPSupplier90%
DYNAVAXDYNAVAXCustomer92%
HHS-BARDAHHS-BARDACustomer85%
+38 more relationships locked
Subscribe — View plans →